Metraipolis › archive › dc_43f2e8967565

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41426315
DOI
10.3389/fonc.2025.1637973
License (as archived)
solo-consultazione
Archived
2026-11-07T21:40:39.712Z
SHA-256 of the archived text
1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c
Stable URL of this page
https://metraipolis.com/documento/dc_43f2e8967565

How to cite

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315 — Europe PMC (en), https://europepmc.org/article/MED/41426315 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_43f2e8967565 (Metraipolis archive dc_43f2e8967565, sha256 1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c)
BibTeX
@misc{dc43f2e8967565,
  title = {Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41426315},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_43f2e8967565; sha256 1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41426315. Agents can read the archived copy with the MCP tool read_document.